Expression Of Potassium Channel Tetramerization Structural Domain 5 In Pancreatic Cancer And Its Clinical Significance

Background:Pancreatic carcinoma(PC)is a highly complex and aggressive malignancy that ranks sixth in cancer-related deaths,with a higher incidence in women than in men.Radical surgical treatment is the only way to achieve long-term survival in PC patients,but PC starts insidiously and most patients are known to be advanced at the time of diagnosis,losing the opportunity for surgery.Due to the genetic complexity and cellular heterogeneity of PC,PC is resistant to most drug treatments.Currently,treatment for advanced PC is often limited to chemotherapy,immunotherapy,and targeted therapy,but the prognosis of PC patients is extremely poor.Therefore,there is an urgent need to establish a systematic diagnosis and treatment system of biologically sensitive markers applied to the treatment of PC.Objective:To investigate the expression of KCTD5 in PC and its effect on the proliferation,migration,invasion and apoptosis ability of pancreatic cancer cells.Method:The mRNA expression level of KCTD5 in pancreatic cancer was investigated in the TCGA database,and the correlation between the expression level of KCTD5 in pancreatic cancer tissues and normal pancreatic tissues and the clinicopathological parameters of pancreatic cancer was analyzed.The expression levels of pancreatic cancer cell lines(SW1990,PANC-1,ASPC-1)and their normal pancreatic ductal epithelial cells(HPDE)were detected by quantitative polymerase chain reaction(qPCR)and protein immunoblotting(Western Blot,WB),respectively.The effect of KCTD5 on the proliferation ability of pancreatic cancer cells was detected by the CCK-8 kit(CCK-8)assay;the effect of KCTD5 on the migration and invasion ability of pancreatic cancer cells was detected by Transwell and scratch healing assays,The effect of KCTD5 on the migration and invasion ability of pancreatic cancer cells was detected by Transwell and scratch healing assays,and the apoptosis of pancreatic cancer cells was detected by flowcytometry assay after reducing KCTD5 expression.Result:Bioinformatics showed that the mRNA and protein expression levels of KCTD5 were significantly higher in pancreatic cancer than in normal tissues(P<0.001,P<0.001),and the differences were statistically significant;univariate analysis and survival analysis showed that KCTD5 could be a risk factor affecting the prognosis of pancreatic cancer patients(P<0.01,P<0.01),and the differences were statistically significant;KCTD5 expression was significantly correlated with TNM stage and tumor grade in PC patients(P<0.05),and the differences were statistically significant.expression was significantly correlated with TNM stage and tumor grade of PC patients(P<0.05),and the difference was statistically significant.qPCR and Western Blot results showed that the expression level of KCTD5 in pancreatic cancer cells was significantly higher than that in normal pancreatic cells(P<0.05).After cell transfection,CCK-8 assay showed that reducing KCTD5 significantly inhibited the proliferation ability of pancreatic cancer cell lines(P<0.05);Transwell and scratch healing assays showed that reducing KCTD5 expression significantly reduced the migration and invasion ability of pancreatic cancer cells(P<0.05,P<0.05);flow cytometry assay showed that reducing KCTD5 expression The results of flow cytometry showed that reducing KCTD5 expression significantly promoted apoptosis of pancreatic cancer cells(P<0.05).Conclusion:1.KCTD5 mRNA and protein level expression were upregulated in pancreatic cancer.2.The expression of KCTD5 was closely related to TNM stage and tumor grade in clinicopathological parameters of pancreatic cancer patients.3.Reducing the expression of KCTD5 significantly inhibited the proliferation and migration ability of pancreatic cancer cells and promoted apoptosis of pancreatic cancer cells.